logo

Ligand Pharmaceuticals Inc (LGND)



Trade LGND now with
  Date
  Headline
12/2/2019 8:33:41 AM Ligand Enters Worldwide OmniAb License Agreement With Sanofi
11/8/2019 8:34:50 AM Ligand Pharma Unveils Positive Results From Phase 1 Trial of Captisol-enabled Iohexol Program At ASN Kidney Week 2019
11/5/2019 4:09:34 PM Ligand Pharmaceuticals Inc (LGND) Has Lowered Its 2019 EPS Estimate To 3.00 From 3.20
11/5/2019 4:05:24 PM Ligand Pharmaceuticals Q3 Loss Per Share $0.81 Vs EPS $2.80 Prior Year
10/15/2019 9:05:33 AM Ligand Appoints Sarah Boyce To Board
7/30/2019 8:04:00 AM Ligand Pharma Q2 Loss Per Share $0.74 Vs Profit $2.99 Last Year
7/23/2019 4:35:39 PM Ligand Pharmaceuticals Acquires Ab Initio Biotherapeutics
7/10/2019 9:05:07 AM Ligand Report Positive Top Line Results From Phase 1 Trial Of CE Iohexol Program
7/8/2019 8:32:14 AM Ligand And SQ Innovation Enter Into Exclusive Worldwide Captisol License And Supply Deals For Furosemide Formulation
3/21/2019 9:10:04 AM Ligand To Receive $3 Mln Milestone Payment As Result Of FDA Approval Of Sage Therapeutics’ ZULRESSOTM Injection
2/7/2019 5:14:03 PM Ligand Pharma Q4 Loss/share $2.02 Vs. Loss $0.33 Year Ago
2/7/2019 9:00:35 AM Ligand Pharmaceuticals Enters Worldwide OmniAb Partnership With Genagon Therapeutics AB
2/4/2019 4:12:23 PM Ligand Announces Closing Investment In Dianomi Therapeutics
1/25/2019 9:02:35 AM Ligand Partner Seelos Therapeutics Becomes Public Company
  
 
>